Private Label Tranexamic Acid Eye Cream Manufacturer Low MOQ

The minimum order quantity for a private label tranexamic acid eye cream depends on whether you are working from a manufacturer's existing stock base or commissioning a custom formula. Stock-base private label programs — where the manufacturer already has a validated tranexamic acid eye-area emulsion and you add your logo and packaging — typically start at 200 to 500 units. This is the fastest and most capital-efficient entry point for new brands. Semi-custom programs, where you modify an existing base by adjusting active concentrations, tweaking the emollient system, or adding a peptide booster, usually require 500 to 1,000 units because the manufacturer must run a small-batch reformulation and additional stability checks before production. Fully custom formulas — where you own the INCI deck and the formula is developed exclusively for your brand — generally require 1,000 to 2,000 units as a first run, though some specialty low-MOQ labs in the U.S. and South Korea will go as low as 500 units with a higher per-unit cost to cover their setup economics. Several factors push MOQ up: airless pump components with high minimum tooling runs, specialty packaging like glass with metallic closures, and any claims-substantiation studies (clinical or consumer) that the manufacturer must amortize across units. Factors that pull MOQ down include using the manufacturer's stock packaging, committing to repeat orders in your contract, or selecting a lab that specifically serves indie brands. A common mistake founders make is negotiating MOQ in isolation from unit cost. A manufacturer offering 200-unit MOQ at $16 per unit may be less economical at scale than one offering 1,000 units at $7 per unit, depending on your sell-through velocity. Model both scenarios before signing. AJ Cosmo Labs lets you filter the manufacturer marketplace by MOQ directly from the iOS app, so you can surface only partners who match your current production capacity without wading through suppliers built for mass-market volume.

Lead times for private label tranexamic acid eye cream manufacturing fall into distinct phases, and understanding each one helps you build a realistic product launch calendar. For stock-base private label, where the formulation already exists and is validated, the total timeline is typically 4 to 8 weeks: 1 to 2 weeks for contract and artwork sign-off, 1 to 2 weeks for label printing and component procurement, and 2 to 4 weeks for filling, quality control, and shipment. This is the fastest path to market. For semi-custom modifications, add a formulation and bench-testing phase of 3 to 6 weeks before production begins, bringing the total to 8 to 14 weeks. The cosmetic chemist must verify that any changes to the base do not affect preservative efficacy, pH stability, or active compatibility at the eye-area pH target of 5.5 to 6.5. Fully custom formulations take the longest: 4 to 8 weeks for initial development and bench iteration, 4 to 6 weeks for accelerated stability (40°C/75% RH), 2 to 4 weeks for safety and ocular tolerance screening, and 2 to 4 weeks for production once all data is signed off. Total: 12 to 22 weeks. Brands that need real-time stability data (24-month shelf-life claim) are looking at ongoing data collection in parallel with launch. The most common delay point is packaging lead time. Airless pumps, especially PCR or custom-decorated components, can have 10 to 16 week tooling and manufacturing lead times from suppliers in Asia. Founders who do not lock packaging specifications early often push their manufacturing timeline out by months. Another frequent delay: incomplete regulatory documentation. For U.S. MoCRA compliance and EU Responsible Person submission, safety dossiers must be complete before product can legally ship. Build this into your project plan, not as an afterthought. Using AJ Cosmo Labs to post a detailed product brief and communicate with manufacturers through the app's built-in messaging keeps all timeline milestones visible and documented in one place, reducing the back-and-forth that typically adds weeks to a project.

Cost for private label tranexamic acid eye cream manufacturing breaks into three buckets: development fees, per-unit production cost, and ancillary costs like testing and regulatory documentation. Development fees for a fully custom formula typically run $1,500 to $5,000 and cover the cosmetic chemist's time, raw material sourcing, bench iterations, and preliminary stability setup. Many manufacturers credit part or all of this fee against your first production order once you hit a specified volume. Stock-base private label programs usually charge no development fee, or a nominal $300 to $500 for minor modifications. Per-unit production cost (formula plus filling, excludes packaging) for a 15 mL to 30 mL eye cream runs approximately $2.50 to $9.00 depending on formula complexity, active concentrations, and run size. When you layer in packaging — a standard airless pump is $0.80 to $2.00 per unit; a specialty glass jar with metallic closure is $2.00 to $4.50 per unit — total landed cost before any testing or shipping is typically $4 to $18 per unit at low-to-mid MOQ. Testing is a significant ancillary cost founders often underestimate. An HRIPT for eye-area safety runs $3,000 to $8,000. Accelerated stability panels run $1,500 to $4,000 per formula. A preservative efficacy test (PET/challenge test) runs $600 to $1,200. For EU entry, a qualified safety assessor's CPSR fee is typically $800 to $2,500. At a 500-unit run, amortizing $4,000 in development and $4,000 in testing across units adds $16 to unit economics — significant for a product you plan to sell at $28 to $45 retail. At 2,000 units those fixed costs drop to $4 per unit, which is why scaling from a pilot run matters for margin. The per-unit cost band that typically supports a healthy DTC margin (aiming for a 65–70% gross margin) is $5 to $10 all-in for a product retailing at $30 to $45. That benchmark is achievable at 1,000+ units with a semi-custom formula and stock packaging.

Tranexamic acid concentrations in topical cosmetic formulations for eye-area use typically range from 2% to 5% by weight, with the majority of commercially successful brightening eye creams landing at 2% to 3%. This range is supported by the clinical literature on tranexamic acid's mechanism — inhibition of plasminogen activator in melanocytes — while remaining within a tolerability window appropriate for periorbital skin. Concentrations above 5% are rare in rinse-off products and essentially absent in leave-on eye-area formulas. At higher concentrations, the risk of formulation instability increases — tranexamic acid can interact with certain chelating agents and alter emulsion texture — and tolerance benefits diminish without proportional efficacy gains. The most important formulation consideration is not just concentration but the supporting ingredient deck. Tranexamic acid at 3% paired with niacinamide at 4% and a peptide complex (e.g., palmitoyl tripeptide-5 or acetyl tetrapeptide-5) produces a more clinically meaningful outcome than 5% tranexamic acid in an otherwise undifferentiated emulsion. Your cosmetic chemist should be designing a system, not just hitting a number. For regulatory purposes, tranexamic acid is not currently restricted by concentration in U.S. FDA cosmetic regulations or EU Cosmetics Regulation annexes as of 2024, meaning it can be used at cosmetically effective levels without requiring drug approval in either market — provided label claims stay in cosmetic territory ("reduces the appearance of dark circles" vs. "treats hyperpigmentation"). When evaluating a manufacturer's stock base, request the full INCI list and the percentage range for tranexamic acid. Some stock formulas list it as low as 0.5% to 1%, which is below efficacy thresholds supported by the literature. A manufacturer who cannot or will not confirm active percentages is a supplier to avoid for any efficacy-adjacent formula. AJ Cosmo Labs manufacturers in the cosmetics category are listed with their formulation specialties and active ingredient capabilities, so you can narrow your search to suppliers with documented experience at efficacy-level tranexamic acid concentrations before you ever open a conversation.

No FDA pre-market approval is required to sell a tranexamic acid eye cream in the United States, provided the product is positioned and labeled as a cosmetic. The FDA regulates cosmetics under the Federal Food, Drug, and Cosmetic Act and the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which added significant new requirements but does not require pre-approval for cosmetics. Under MoCRA, all cosmetic facilities that manufacture or process cosmetics for U.S. distribution must register with the FDA, and all cosmetic products must be listed through the FDA's registration portal. These requirements phased in starting December 2023 for large companies and December 2024 for small businesses. Your contract manufacturer should already have their facility registration in place; confirm this before signing any production agreement. MoCRA also requires that brands maintain safety substantiation records — documentation that the product is safe for its labeled use — and that there is an adverse event reporting mechanism in place. For an eye-area leave-on product, safety substantiation typically includes the manufacturer's raw material safety data, formulation stability data, and where available, human tolerance testing. The boundary that brands must not cross is a drug claim. If your eye cream labeling or marketing implies that the product treats, prevents, or cures a condition — for example, "treats periorbital hyperpigmentation" or "corrects dark circles caused by vascular dysfunction" — the FDA may classify the product as a drug, triggering pre-market approval requirements and manufacturing standards under 21 CFR Part 211. "Visibly reduces the appearance of dark circles" is cosmetic language. "Treats dark circles" is not. For sales in California, Prop 65 requires a warning label if the product contains any listed chemical above safe harbor levels. Your manufacturer should provide a Prop 65 compliance review as part of their documentation package. If you plan to sell in both the U.S. and EU simultaneously, factor in the EU Cosmetic Product Safety Report (CPSR) requirement, which must be completed by a qualified safety assessor and submitted to the Responsible Person before market entry. This adds cost but is mandatory and non-negotiable for EU distribution.

Finding a vetted low-MOQ cosmetic contract manufacturer for an eye cream — especially one with active-ingredient expertise in tranexamic acid — requires more than a Google search. The challenge is that the internet is saturated with brokers and directories that list manufacturers without verifying GMP status, active ingredient capabilities, or actual minimum order thresholds. The most reliable traditional methods are trade shows (Cosmoprof North America, NYSCC Suppliers' Day, In-Cosmetics), where you can meet manufacturing representatives in person, verify facility credentials on-site, and get references from brands already in production. The downside is that trade shows are annual, expensive to attend, and favor founders who already have contacts in the industry. Referrals from other indie founders are the second most reliable method. Cosmetic formulator communities on platforms like Beauty Independent's forums or LinkedIn groups for indie cosmetic brand founders often surface real manufacturer experiences — both positive and negative — that you cannot get from a manufacturer's own marketing. Vetting criteria that separate serious manufacturers from brokers: they have a physical facility address you can verify via satellite or facility audit, they hold an ISO 22716 certificate with a current expiration date, they can name the specific cosmetic chemist who would lead your project, and they provide a certificate of analysis for tranexamic acid sourced from a named API supplier. The fastest and most efficient path for founders in 2024 is to use a purpose-built B2B marketplace with pre-screened suppliers. AJ Cosmo Labs was built specifically for this workflow. Download the AJ Cosmo Labs iOS app from the App Store, post a product brief describing your tranexamic acid eye cream concept including target MOQ, packaging preference, and any certification requirements, and manufacturers in the network who match your criteria can respond directly. The app's filtering tools let you sort by MOQ, geography, and specialty so you are only in conversations with manufacturers who can actually serve your project. Escrowed payments and in-app messaging keep the entire engagement documented and protected from the first sample request through final production payment.

Packaging selection for a tranexamic acid eye cream is both a formulation compatibility decision and a brand positioning decision, and the two must be aligned before you finalize specifications with your manufacturer. Airless pump dispensers are the industry-standard packaging for active-ingredient eye creams. They prevent oxidation and contamination by keeping air out of the product chamber, which is particularly important for tranexamic acid formulations that may also contain niacinamide or vitamin C derivatives — both of which degrade on repeated air exposure. Airless pumps typically come in 15 mL and 30 mL sizes for eye cream, with unit costs ranging from $0.80 to $2.50 depending on material (PP vs. ABS vs. PCR resin) and decoration (screen print vs. hot stamp). Glass jars with stainless steel or aluminum closures are a premium positioning choice, common in the $45 to $80 retail tier. They offer excellent perceived value and are compatible with most tranexamic acid emulsion systems, but they expose the product to air on every use. For high-active formulations, a manufacturer may recommend adding a secondary antioxidant booster to the formula to compensate. Glass jar unit cost at low MOQ runs $2.00 to $4.50. Roll-on applicators (5 mL to 10 mL) work for lighter, more fluid tranexamic acid eye serums — not traditional cream textures. They provide cooling de-puffing benefit (the metal ball applicator conducts cold from refrigeration) but limit formula viscosity. Not all tranexamic acid eye cream bases are reformulatable into a roll-on without significant texture modification. PCR (post-consumer recycled) resin packaging is increasingly requested by DTC brands targeting sustainability-conscious consumers. PCR airless pumps and tubes are available at low MOQ through most major packaging suppliers, with a cost premium of roughly $0.30 to $0.80 per unit over virgin resin. The most common mistake founders make with packaging is selecting components before the formula viscosity is finalized. An airless pump sized for a thin serum will dispense inconsistently with a richer cream. Always confirm the fill compatibility with your manufacturer's cosmetic chemist — they should test-fill prototype packaging before you order full production quantities.